Oriola and Boehringer Ingelheim continue their cooperation

Boehringer Ingelheim and Oriola are continuing their long-term cooperation. Oriola provides Boehringer Ingelheim with pharmaceutical storage and distribution services  and a wide selection of expert services in Finland.

Oriola and Boehringer Ingelheim have been cooperating since 1956. Their new cooperation agreement was signed on 7th April 2017.

Boehringer Ingelheim is a pharmaceutical company focusing on research, with the aim of developing new, more effective treatments. The company has around 50,000 employees and is among the 20 largest pharmaceutical companies in the world. In 2016, its net sales totalled EUR 15.9 billion, and it invested more than 20 per cent of that total in research and product development. Boehringer Ingelheim has introduced numerous new treatments since 2000. The best-known of these include tiotropium bromide (Spiriva®) for chronic obstructive pulmonary disease, pramipexole (Sifrol®) for Parkinson’s disease and restless leg syndrome, telmisartan (Micardis®) for hypertension, dabigatran etexilate (Pradaxa®) for preventing strokes in patients with atrial fibrillation, among other conditions, and linagliptin (Trajenta®) and empagliflozin (Jardiance®) for type 2 diabetes. The company is preparing to introduce a large number of innovative products over the next few years. Boehringer Ingelheim is one of the fastest-growing pharmaceutical companies in Finland.

“Our goal is to study and develop innovative solutions that bring better health for Finns. We want to be the leading partner in our chosen fields of therapy and cooperate closely with companies that share our goals and values. We are pleased with our long-term cooperation with Oriola and are expecting the good cooperation to continue in the years to come,” says Amos Gyllenbögel, Managing Director of Boehringer Ingelheim Finland. 

Oriola is equally pleased with the close cooperation over the years.

“We are delighted that our cooperation is continuing. Our collaboration is based on openness, straightforwardness and mutual trust,” says Annastiina Palmroth-Holst, Business Unit Director, Services, at Oriola.

 

More information:

Oriola

Annastiina Palmroth-Holst
Business Unit Director, Services
tel. +358 10 429 3405
annastiina.palmroth-holst@oriola.com

Boehringer Ingelheim Finland

Amos Gyllenbögel
Managing Director                                                                                                    
tel. + 358 10 3102 900
amos.gyllenbogel@boehringer-ingelheim.com

 

Oriola

Oriola has a solid position in consumer and services business in the pharmaceutical markets in Sweden, Finland and Baltic countries. Oriola provides pharmaceutical companies an effective access to markets and improves consumers' wellbeing by ensuring that pharmaceuticals, health products and services are delivered in a safe and customer-friendly manner. Oriola Corporation’s net sales in 2016 were approximately EUR 1.6 billion. Company has approximately 2,820 employees. Oriola Corporation is listed on NASDAQ OMX Helsinki Ltd. For more information, visit www.oriola-kd.com.


Boehringer Ingelheim

Boehringer Ingelheim is one of the 20 world-leading companies in the pharmaceutical industry. The company operates globally, with a total of around 50,000 employees. Established in 1885, Boehringer Ingelheim is a family-owned company seeking to improve human and animal health by studying, developing, producing and marketing new, innovative pharmaceuticals. Social responsibility is an integral part of its corporate culture.

The net sales of the Boehringer Ingelheim group of companies amounted to EUR 15.9 billion in 2016. The group invested more than 20 per cent of its net sales in research into new pharmaceuticals.

More information: www.boehringer-ingelheim.com/

All news